| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue | 22 | 5 | 6 | 8 |
| Cost of revenue | 97 | 55 | 41 | 36 |
| Amortization of acquired intangible assets | NaN | 0 | 0 | NaN |
| Sales and marketing | 216 | 201 | 220 | 247 |
| General and administrative | 6,356 | 3,505 | 3,670 | 4,384 |
| Research and development | 1,388 | 1,088 | 790 | 787 |
| Total operating expenses | 8,057 | 4,849 | 4,721 | 5,454 |
| Grant income | NaN | 163 | 80 | 18 |
| Operating loss | -8,035 | -4,844 | -4,715 | -5,446 |
| Debt modification expense | NaN | 0 | 0 | NaN |
| Interest income | NaN | 10 | 8 | 8 |
| Interest expense | NaN | 8 | 4 | 4 |
| Change in fair value - equity method investment | NaN | -4,382 | -10,643 | 21,004 |
| Interest income | 19 | NaN | NaN | NaN |
| Change in fair value - senior secured convertible notes | NaN | 100 | 200 | 49 |
| Interest expense | 3 | NaN | NaN | NaN |
| Management fee income | 3,150 | 3,150 | 3,150 | 3,150 |
| Grant income | 168 | NaN | NaN | NaN |
| Other expense | -40 | NaN | NaN | NaN |
| Change in fair value - equity method investment | 1,878 | NaN | NaN | NaN |
| Gain on deconsolidation of subsidiary | NaN | 0 | NaN | NaN |
| Change in fair value - senior secured convertible notes | -3,360 | NaN | NaN | NaN |
| Debt extinguishments loss - senior secured convertible notes | -3,422 | 0 | 0 | -58 |
| Change in fair value - rights liability | 30 | NaN | NaN | NaN |
| Less series b convertible preferred stock dividends earned | NaN | 90 | 88 | 86 |
| Change in fair value - warrant liability | -1,831 | NaN | NaN | NaN |
| Less series c convertible preferred stock dividends earned | NaN | 470 | 481 | 398 |
| Other income (expense), net | 6,971 | -1,167 | -7,609 | 24,069 |
| Less deemed dividend on subsidiary preferred stock attributable to the noncontrolling interests | NaN | 0 | 0 | NaN |
| Income (loss) before provision for income tax | -1,064 | -6,011 | -12,324 | 18,623 |
| Provision for income taxes | 0 | 0 | 0 | NaN |
| Net income (loss) before noncontrolling interests | -1,064 | -6,011 | -12,324 | 18,623 |
| Net loss attributable to the noncontrolling interests | -1,004 | -628 | -403 | -345 |
| Net income (loss) attributable to pavmed | -60 | -5,383 | -11,921 | 18,968 |
| Less series b convertible preferred stock dividends earned-Series BPreferred Stock | 94 | NaN | NaN | NaN |
| Less series b convertible preferred stock dividends earned-Series CPreferred Stock | 145 | NaN | NaN | NaN |
| Less deemed dividend on series c convertible preferred stock | NaN | -385 | -818 | -789 |
| Less deemed dividend on series c convertible preferred stock-Series CPreferred Stock | 6,689 | NaN | NaN | NaN |
| Net income (loss) attributable to pavmed common stockholders | -6,988 | -6,328 | -13,308 | 17,695 |
| Basic EPS | -4.42 | -0.29 | -0.74 | 1.28 |
| Diluted EPS | -4.42 | -0.29 | -0.74 | 0.34 |
| Basic Average Shares | 1,580,788 | 21,554,546 | 18,084,653 | 13,876,165 |
| Diluted Average Shares | 1,580,788 | 21,554,546 | 18,084,653 | 52,496,401 |
PAVmed Inc. (PAVM)
PAVmed Inc. (PAVM)